Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 7:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,144 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Grippe Clear all

Conditions: Influenza
Interventions: Fluzone; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 10 Weeks to 22 Weeks
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 2
States / cities: Cincinnati, Ohio • Nashville, Tennessee

Conditions: Influenza
Interventions: Inactivated Influenza A Vaccine A/H5N1; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Swiftwater, Pennsylvania

Conditions: Acellular Pertussis, Diphtheria, Tetanus
Interventions: Fluarix®, Boostrix®; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 19 Years and older
Enrollment: 1,726 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 12
States / cities: Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 8 more

Conditions: Cancer
Interventions: FluMist, Inactivated influenza vaccine; Biological
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 21 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Influenza
Interventions: Text message reminder; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 6 Months to 18 Years
Enrollment: 228,361 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Immune Response
Interventions: Flulaval, Fluvirin, Fluzone, Fluarix, Afluria; Biological
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 193 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Influenza
Interventions: Inactivated Influenza A Vaccine A/H5N1, Placebo (IM), Placebo (ID); Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 227 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Upper Respiratory Disease, Influenza, Viral Upper Respiratory Infection
Interventions: Immune Defense Protein 50mg Dose, IDP 200mg Dose, Matching Placebo; Dietary Supplement
Lead sponsor: Quantec Ltd; Industry
Eligibility: 60 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: No Conditions
Interventions: Health Education, Health Education Training; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 50 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Influenza, Acute Respiratory Infection, Influenza-like Illness
Interventions: Educational text messages; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: Not listed
Enrollment: 1,918 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza, Respiratory Tract Infections
Interventions: Enhanced texts with Callback by a Person, Enhanced Bidirectional Texts; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 6 Months and older
Enrollment: 246,295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Influenza
Interventions: Quadrivalent RIV with H3 strain 1, Quadrivalent RIV with H3 strain 2, Quadrivalent RIV with H3 strain 3, Quadrivalent RIV with H3 strain 4, Quadrivalent RIV with 2018-2019 NH H3 strain; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years to 30 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Hollywood, Florida • Rochester, New York • North Charleston, South Carolina

Conditions: Influenza
Interventions: favipiravir, Placebo; Drug
Lead sponsor: MDVI, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 860 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 60
States / cities: Birmingham, Alabama • Hunstville, Alabama • Hot Springs, Arkansas + 48 more

Conditions: Influenza
Interventions: CAIV-T, TIV; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 6 Months to 36 Months
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 5
States / cities: Layton, Utah • Ogden, Utah • Pleasant Grove, Utah + 2 more

Conditions: Influenza
Interventions: Fluzone vaccine with JVRS-100 adjuvant, Fluzone vaccine; Biological
Lead sponsor: Colby Pharmaceutical Company; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Miami, Florida • Lenexa, Kansas

Conditions: Influenza, Human
Interventions: Flu Symptoms; Device
Lead sponsor: Sekisui Diagnostics, LLC; Industry
Eligibility: 3 Months and older
Enrollment: 677 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 3
States / cities: Winston-Salem, North Carolina • Charleston, South Carolina • New Braunfels, Texas

Conditions: Influenza
Interventions: Inactivated H1N1 Vaccine, Trivalent Inactivated Influenza Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Months to 17 Years
Enrollment: 531 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: Atlanta, Georgia • Iowa City, Iowa • St Louis, Missouri + 4 more

Conditions: Influenza A Virus Infection
Interventions: Collection of Anti-Influenza A Immune Plasma; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 59 Years · Male only
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2019
U.S. locations: 2
States / cities: San Diego, California • Bethesda, Maryland

Conditions: Respiratory Syncytial Virus Infections
Interventions: RSVPreF3 OA investigational vaccine, FLU HD vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 65 Years and older
Enrollment: 1,029 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 46
States / cities: Birmingham, Alabama • Tempe, Arizona • Canoga Park, California + 41 more

Conditions: Infertility, Recurrent Miscarriage
Interventions: Influenza Vaccine, Sterile Saline; Biological · Other
Lead sponsor: Center for Human Reproduction; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 126 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza, COVID-19
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: SARS-CoV-2 Infection, Influenza A, Influenza Type B, RSV Infection
Interventions: The Applied Biosystems™ TaqPath™ COVID-19, Flu A, Flu B, RSV Select Panel; Diagnostic Test
Lead sponsor: Thermo Fisher Scientific, Inc; Industry
Eligibility: Not listed
Enrollment: 1,909 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 17
States / cities: San Diego, California • Lake City, Florida • Miami, Florida + 13 more

Conditions: Influenza, Human
Interventions: Elderberry Extract, Placebos; Drug
Lead sponsor: michael macknin; Other
Eligibility: 5 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Influenza
Interventions: Influenza virus vaccine (Pediatric formulation); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 36 Months
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Norfolk, Virginia

Search by objective public record fields.

Inactivated Influenza Vaccine in Infants 10-22 Weeks of Age

Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities

Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adults

A Study of a Live Intranasal Influenza Vaccine in Children With Cancer

Influenza Reminder Text-Messaging

Immune Responses Induced by Different Licensed Influenza Vaccines

Higher Dose Intradermal H5 Vaccine

Immune Defense Protein Impact On Respiratory Immune Outcomes

Health Management Training to Enhance Influenza Vaccine Immunogenicity

FluSAFE: Flu SMS Alerts to Freeze Exposure

Patient Portal Flu Vaccine Reminders_RCT 5 (LADHS)

Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age

Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults - T705US316

Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)

Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant

Clinical Performance Study of the Ultra Influenza A&B Test Using Nasal Swabs for Identifying Subjects Who Are Infected With the Influenza Virus Strain Type A or Type B

Sanofi Pasteur, TIV + H1N1, Pediatric Population

Blood and Plasma Collection For Use in Future Clinical Trials

A Study on the Immune Response and Safety Elicited by a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a Vaccine Against Influenza in Adults Aged 65 Years and Above

Effect of Influenza Vaccination on Donor Egg Recipient Outcomes

Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination

Project STARFISH - PRJ0002679

Evaluating The Safety And Clinical Efficacy Of Elderberry Extract In Patients With Influenza

Study to Collect Sera for Immunogenicity Testing in Children Vaccinated With Fluzone®